S&P 500   3,728.03 (-2.40%)
DOW   30,580.96 (-2.20%)
QQQ   303.79 (-1.74%)
AAPL   120.21 (-1.52%)
MSFT   226.73 (-0.36%)
FB   257.18 (+0.69%)
GOOGL   2,030.11 (+0.93%)
TSLA   614.74 (-5.89%)
AMZN   2,992.49 (-0.42%)
NVDA   490.53 (-4.23%)
BABA   230.82 (-2.31%)
CGC   30.94 (-6.92%)
GE   13.42 (-0.15%)
MU   83.34 (-6.48%)
NIO   39.33 (-5.30%)
AMD   77.98 (-3.56%)
T   28.90 (+0.63%)
F   11.89 (-2.30%)
ACB   9.71 (-7.17%)
DIS   186.87 (-2.80%)
BA   224.62 (-1.72%)
NFLX   516.02 (-0.90%)
PFE   34.15 (-0.70%)
S&P 500   3,728.03 (-2.40%)
DOW   30,580.96 (-2.20%)
QQQ   303.79 (-1.74%)
AAPL   120.21 (-1.52%)
MSFT   226.73 (-0.36%)
FB   257.18 (+0.69%)
GOOGL   2,030.11 (+0.93%)
TSLA   614.74 (-5.89%)
AMZN   2,992.49 (-0.42%)
NVDA   490.53 (-4.23%)
BABA   230.82 (-2.31%)
CGC   30.94 (-6.92%)
GE   13.42 (-0.15%)
MU   83.34 (-6.48%)
NIO   39.33 (-5.30%)
AMD   77.98 (-3.56%)
T   28.90 (+0.63%)
F   11.89 (-2.30%)
ACB   9.71 (-7.17%)
DIS   186.87 (-2.80%)
BA   224.62 (-1.72%)
NFLX   516.02 (-0.90%)
PFE   34.15 (-0.70%)
S&P 500   3,728.03 (-2.40%)
DOW   30,580.96 (-2.20%)
QQQ   303.79 (-1.74%)
AAPL   120.21 (-1.52%)
MSFT   226.73 (-0.36%)
FB   257.18 (+0.69%)
GOOGL   2,030.11 (+0.93%)
TSLA   614.74 (-5.89%)
AMZN   2,992.49 (-0.42%)
NVDA   490.53 (-4.23%)
BABA   230.82 (-2.31%)
CGC   30.94 (-6.92%)
GE   13.42 (-0.15%)
MU   83.34 (-6.48%)
NIO   39.33 (-5.30%)
AMD   77.98 (-3.56%)
T   28.90 (+0.63%)
F   11.89 (-2.30%)
ACB   9.71 (-7.17%)
DIS   186.87 (-2.80%)
BA   224.62 (-1.72%)
NFLX   516.02 (-0.90%)
PFE   34.15 (-0.70%)
S&P 500   3,728.03 (-2.40%)
DOW   30,580.96 (-2.20%)
QQQ   303.79 (-1.74%)
AAPL   120.21 (-1.52%)
MSFT   226.73 (-0.36%)
FB   257.18 (+0.69%)
GOOGL   2,030.11 (+0.93%)
TSLA   614.74 (-5.89%)
AMZN   2,992.49 (-0.42%)
NVDA   490.53 (-4.23%)
BABA   230.82 (-2.31%)
CGC   30.94 (-6.92%)
GE   13.42 (-0.15%)
MU   83.34 (-6.48%)
NIO   39.33 (-5.30%)
AMD   77.98 (-3.56%)
T   28.90 (+0.63%)
F   11.89 (-2.30%)
ACB   9.71 (-7.17%)
DIS   186.87 (-2.80%)
BA   224.62 (-1.72%)
NFLX   516.02 (-0.90%)
PFE   34.15 (-0.70%)
Log in
NASDAQ:MBRX

Moleculin Biotech Competitors

$3.72
-0.31 (-7.69 %)
(As of 03/4/2021 01:25 PM ET)
Add
Compare
Today's Range
$3.72
Now: $3.72▼
$4.00
50-Day Range
$0.83
MA: $5.03▼
$6.42
52-Week Range
$1.94
Now: $3.72▼
$11.82
Volume4,323 shs
Average Volume3.36 million shs
Market Capitalization$97.76 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11

Competitors

Moleculin Biotech (NASDAQ:MBRX) Vs. RAPT, MEIP, PBYI, BDSI, XOMA, and VRCA

Should you be buying MBRX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Moleculin Biotech, including RAPT Therapeutics (RAPT), MEI Pharma (MEIP), Puma Biotechnology (PBYI), BioDelivery Sciences International (BDSI), XOMA (XOMA), and Verrica Pharmaceuticals (VRCA).

Moleculin Biotech vs. RAPT Therapeutics Stock

RAPT Therapeutics (NASDAQ:RAPT) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for RAPT Therapeutics and Moleculin Biotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RAPT Therapeutics00503.00
Moleculin Biotech00203.00

RAPT Therapeutics presently has a consensus price target of $40.80, indicating a potential upside of 155.00%. Moleculin Biotech has a consensus price target of $15.00, indicating a potential upside of 303.23%. Given Moleculin Biotech's higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than RAPT Therapeutics.

Risk & Volatility

RAPT Therapeutics has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500.

Profitability

This table compares RAPT Therapeutics and Moleculin Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RAPT TherapeuticsN/A-48.78%-42.35%
Moleculin BiotechN/A-113.25%-63.20%

Earnings and Valuation

This table compares RAPT Therapeutics and Moleculin Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RAPT TherapeuticsN/AN/A$-43,000,000.00($9.89)-1.62
Moleculin BiotechN/AN/A$-13,200,000.00($0.32)-11.63

Moleculin Biotech is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

65.0% of RAPT Therapeutics shares are held by institutional investors. Comparatively, 4.8% of Moleculin Biotech shares are held by institutional investors. 31.0% of RAPT Therapeutics shares are held by insiders. Comparatively, 8.3% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

RAPT Therapeutics beats Moleculin Biotech on 6 of the 10 factors compared between the two stocks.

Moleculin Biotech vs. MEI Pharma Stock

MEI Pharma (NASDAQ:MEIP) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for MEI Pharma and Moleculin Biotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MEI Pharma01602.86
Moleculin Biotech00203.00

MEI Pharma presently has a consensus price target of $10.60, indicating a potential upside of 209.04%. Moleculin Biotech has a consensus price target of $15.00, indicating a potential upside of 303.23%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than MEI Pharma.

Risk & Volatility

MEI Pharma has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500.

Profitability

This table compares MEI Pharma and Moleculin Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MEI Pharma-142.81%-33.55%-16.70%
Moleculin BiotechN/A-113.25%-63.20%

Earnings and Valuation

This table compares MEI Pharma and Moleculin Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MEI Pharma$28.91 million13.35$-46,010,000.00($0.26)-13.19
Moleculin BiotechN/AN/A$-13,200,000.00($0.32)-11.63

Moleculin Biotech has lower revenue, but higher earnings than MEI Pharma. MEI Pharma is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

67.6% of MEI Pharma shares are held by institutional investors. Comparatively, 4.8% of Moleculin Biotech shares are held by institutional investors. 4.4% of MEI Pharma shares are held by insiders. Comparatively, 8.3% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

MEI Pharma beats Moleculin Biotech on 7 of the 13 factors compared between the two stocks.

Moleculin Biotech vs. Puma Biotechnology Stock

Puma Biotechnology (NASDAQ:PBYI) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Puma Biotechnology and Moleculin Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Puma Biotechnology-23.86%-451.50%-22.80%
Moleculin BiotechN/A-113.25%-63.20%

Volatility and Risk

Puma Biotechnology has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.

Insider & Institutional Ownership

87.9% of Puma Biotechnology shares are held by institutional investors. Comparatively, 4.8% of Moleculin Biotech shares are held by institutional investors. 21.2% of Puma Biotechnology shares are held by company insiders. Comparatively, 8.3% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Puma Biotechnology and Moleculin Biotech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Puma Biotechnology$272.30 million1.53$-75,600,000.00($1.95)-5.38
Moleculin BiotechN/AN/A$-13,200,000.00($0.32)-11.63

Moleculin Biotech has lower revenue, but higher earnings than Puma Biotechnology. Moleculin Biotech is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Puma Biotechnology and Moleculin Biotech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Puma Biotechnology14102.00
Moleculin Biotech00203.00

Puma Biotechnology presently has a consensus target price of $12.50, indicating a potential upside of 19.16%. Moleculin Biotech has a consensus target price of $15.00, indicating a potential upside of 303.23%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than Puma Biotechnology.

Summary

Moleculin Biotech beats Puma Biotechnology on 8 of the 13 factors compared between the two stocks.

Moleculin Biotech vs. BioDelivery Sciences International Stock

BioDelivery Sciences International (NASDAQ:BDSI) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares BioDelivery Sciences International and Moleculin Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioDelivery Sciences International10.16%25.04%9.89%
Moleculin BiotechN/A-113.25%-63.20%

Volatility and Risk

BioDelivery Sciences International has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.

Insider & Institutional Ownership

67.4% of BioDelivery Sciences International shares are held by institutional investors. Comparatively, 4.8% of Moleculin Biotech shares are held by institutional investors. 8.6% of BioDelivery Sciences International shares are held by company insiders. Comparatively, 8.3% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares BioDelivery Sciences International and Moleculin Biotech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioDelivery Sciences International$111.39 million3.59$-15,310,000.00$0.1039.60
Moleculin BiotechN/AN/A$-13,200,000.00($0.32)-11.63

Moleculin Biotech has lower revenue, but higher earnings than BioDelivery Sciences International. Moleculin Biotech is trading at a lower price-to-earnings ratio than BioDelivery Sciences International, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for BioDelivery Sciences International and Moleculin Biotech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioDelivery Sciences International01402.80
Moleculin Biotech00203.00

BioDelivery Sciences International presently has a consensus target price of $8.45, indicating a potential upside of 113.38%. Moleculin Biotech has a consensus target price of $15.00, indicating a potential upside of 303.23%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than BioDelivery Sciences International.

Summary

BioDelivery Sciences International beats Moleculin Biotech on 9 of the 13 factors compared between the two stocks.

Moleculin Biotech vs. XOMA Stock

XOMA (NASDAQ:XOMA) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Insider & Institutional Ownership

57.2% of XOMA shares are held by institutional investors. Comparatively, 4.8% of Moleculin Biotech shares are held by institutional investors. 9.9% of XOMA shares are held by company insiders. Comparatively, 8.3% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares XOMA and Moleculin Biotech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA$18.37 million21.01$-1,980,000.00($0.23)-152.26
Moleculin BiotechN/AN/A$-13,200,000.00($0.32)-11.63

XOMA has higher revenue and earnings than Moleculin Biotech. XOMA is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for XOMA and Moleculin Biotech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
XOMA00203.00
Moleculin Biotech00203.00

XOMA presently has a consensus target price of $46.00, indicating a potential upside of 31.35%. Moleculin Biotech has a consensus target price of $15.00, indicating a potential upside of 303.23%. Given Moleculin Biotech's higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than XOMA.

Profitability

This table compares XOMA and Moleculin Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
XOMA-102.23%-28.83%-11.91%
Moleculin BiotechN/A-113.25%-63.20%

Volatility and Risk

XOMA has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.

Summary

XOMA beats Moleculin Biotech on 7 of the 11 factors compared between the two stocks.

Moleculin Biotech vs. Verrica Pharmaceuticals Stock

Moleculin Biotech (NASDAQ:MBRX) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Insider and Institutional Ownership

4.8% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 34.0% of Verrica Pharmaceuticals shares are owned by institutional investors. 8.3% of Moleculin Biotech shares are owned by company insiders. Comparatively, 40.2% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Moleculin Biotech and Verrica Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moleculin BiotechN/AN/A$-13,200,000.00($0.32)-11.63
Verrica PharmaceuticalsN/AN/A$-28,210,000.00($1.13)-11.95

Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Moleculin Biotech and Verrica Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Moleculin Biotech00203.00
Verrica Pharmaceuticals01302.75

Moleculin Biotech currently has a consensus target price of $15.00, indicating a potential upside of 303.23%. Verrica Pharmaceuticals has a consensus target price of $15.75, indicating a potential upside of 16.67%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Moleculin Biotech is more favorable than Verrica Pharmaceuticals.

Profitability

This table compares Moleculin Biotech and Verrica Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Moleculin BiotechN/A-113.25%-63.20%
Verrica PharmaceuticalsN/A-54.53%-40.42%

Volatility and Risk

Moleculin Biotech has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500.

Summary

Verrica Pharmaceuticals beats Moleculin Biotech on 7 of the 11 factors compared between the two stocks.


Moleculin Biotech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$16.00-5.9%$416.21 millionN/A-6.30Unusual Options Activity
News Coverage
MEI Pharma logo
MEIP
MEI Pharma
1.7$3.43-6.7%$411.85 million$28.91 million-5.72
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.4$10.49-1.5%$410.74 million$272.30 million-7.34
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.2$3.96-2.5%$410.51 million$111.39 million28.29Upcoming Earnings
Analyst Upgrade
News Coverage
XOMA logo
XOMA
XOMA
1.8$35.02-3.2%$398.45 million$18.37 million-31.55Upcoming Earnings
Decrease in Short Interest
Verrica Pharmaceuticals logo
VRCA
Verrica Pharmaceuticals
1.1$13.50-12.1%$391.35 millionN/A-10.23News Coverage
Gap Up
Verastem logo
VSTM
Verastem
1.8$2.22-2.7%$387.09 million$17.46 million-1.57Upcoming Earnings
Gap Up
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$3.51-4.8%$381.43 million$102.31 million5.24
VYNE Therapeutics logo
VYNE
VYNE Therapeutics
1.9$6.50-13.8%$379.82 million$10.64 million-1.73Gap Up
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.65-7.3%$379.50 million$57.49 million-6.43Analyst Downgrade
Analyst Revision
Cue Biopharma logo
CUE
Cue Biopharma
1.3$12.13-2.7%$377.26 million$3.46 million-7.73
Graybug Vision logo
GRAY
Graybug Vision
2.0$16.65-7.6%$375.73 millionN/A0.00Increase in Short Interest
Gap Up
Immunome logo
IMNM
Immunome
1.1$29.03-22.6%$375.19 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Aeglea BioTherapeutics logo
AGLE
Aeglea BioTherapeutics
1.7$7.19-8.8%$374.87 million$3.89 million-3.76Upcoming Earnings
Forte Biosciences logo
FBRX
Forte Biosciences
1.6$25.97-12.2%$373.77 million$40,000.00-1.13Gap Up
Athersys logo
ATHX
Athersys
1.3$1.77-6.2%$371.68 million$5.63 million-4.78
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.5$1.01-12.4%$366.02 millionN/A-0.28Increase in Short Interest
Gap Up
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.7$28.52-2.5%$361.22 million$206.55 million-14.33Upcoming Earnings
CymaBay Therapeutics logo
CBAY
CymaBay Therapeutics
1.6$4.48-11.6%$344.44 millionN/A-4.77Upcoming Earnings
Increase in Short Interest
NATR
Nature's Sunshine Products
1.0$17.19-1.5%$343.03 million$362.21 million20.71Upcoming Earnings
News Coverage
Oncorus logo
ONCR
Oncorus
1.6$14.17-5.4%$337.91 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
Sesen Bio logo
SESN
Sesen Bio
1.2$2.33-10.3%$332.40 millionN/A-5.30Analyst Upgrade
Decrease in Short Interest
News Coverage
VistaGen Therapeutics logo
VTGN
VistaGen Therapeutics
1.3$2.08-11.5%$328.73 millionN/A-4.33Gap Up
Trevena logo
TRVN
Trevena
1.4$1.95-7.2%$328.19 million$30,000.00-8.48Upcoming Earnings
BELLUS Health logo
BLU
BELLUS Health
1.6$3.86-8.3%$327.45 million$30,000.00-6.54Analyst Downgrade
Decrease in Short Interest
BIVI
BioVie
1.7$15.76-48.6%$325.91 millionN/A0.00Increase in Short Interest
Gap Up
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$6.92-3.0%$325.42 million$16.54 million-2.81Analyst Report
Analyst Revision
News Coverage
Immunic logo
IMUX
Immunic
1.5$14.76-4.1%$325.35 millionN/A-5.00Analyst Revision
RedHill Biopharma logo
RDHL
RedHill Biopharma
1.4$7.40-4.9%$322.72 million$6.29 million-4.25Unusual Options Activity
Gap Down
NXTC
NextCure
1.6$10.64-8.5%$317.96 million$6.35 million-9.42Upcoming Earnings
Alpine Immune Sciences logo
ALPN
Alpine Immune Sciences
1.8$12.96-2.0%$314.68 million$1.74 million-9.00
Arbutus Biopharma logo
ABUS
Arbutus Biopharma
1.4$3.12-16.7%$309.07 million$6.01 million-2.54Decrease in Short Interest
Analyst Revision
News Coverage
Gap Up
Theratechnologies logo
THTX
Theratechnologies
1.1$3.09-6.1%$307.80 million$63.22 million-9.97Earnings Announcement
Increase in Short Interest
TFF Pharmaceuticals logo
TFFP
TFF Pharmaceuticals
1.4$12.68-7.8%$303.83 millionN/A-4.80Upcoming Earnings
Analyst Upgrade
News Coverage
Evofem Biosciences logo
EVFM
Evofem Biosciences
1.5$3.28-9.8%$292.61 millionN/A-1.68
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.76-10.2%$292.53 million$9.48 million-0.30Upcoming Earnings
Unusual Options Activity
News Coverage
Gap Up
Kamada logo
KMDA
Kamada
1.4$5.99-4.5%$278.70 million$127.19 million12.48Gap Down
MediciNova logo
MNOV
MediciNova
1.2$5.40-3.5%$272.13 millionN/A0.00Decrease in Short Interest
News Coverage
Galera Therapeutics logo
GRTX
Galera Therapeutics
1.6$10.76-0.9%$270.97 millionN/A-3.08Upcoming Earnings
Kezar Life Sciences logo
KZR
Kezar Life Sciences
1.3$5.56-5.2%$270.67 millionN/A-4.45Upcoming Earnings
Increase in Short Interest
LRMR
Larimar Therapeutics
1.7$16.37-5.4%$264.89 millionN/A-3.07News Coverage
Gap Up
Hookipa Pharma logo
HOOK
Hookipa Pharma
1.2$11.35-5.7%$262.21 million$11.94 million-6.92Analyst Downgrade
News Coverage
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$7.52-17.0%$258.46 million$2.71 million-12.97Increase in Short Interest
Gap Up
Cerecor logo
CERC
Cerecor
2.1$3.16-9.2%$258.44 million$6.75 million-10.53Upcoming Earnings
Ovid Therapeutics logo
OVID
Ovid Therapeutics
1.5$3.87-4.4%$256.28 millionN/A-2.74Upcoming Earnings
Analyst Downgrade
Unusual Options Activity
News Coverage
Gap Up
Galecto logo
GLTO
Galecto
1.6$9.76-3.7%$255.64 millionN/A0.00Decrease in Short Interest
News Coverage
Gap Up
Xeris Pharmaceuticals logo
XERS
Xeris Pharmaceuticals
1.6$4.80-7.7%$253.21 million$2.72 million-1.21Upcoming Earnings
Gap Up
Tyme Technologies logo
TYME
Tyme Technologies
1.3$1.78-9.0%$253.03 millionN/A-8.09Increase in Short Interest
Gap Up
Lannett logo
LCI
Lannett
2.0$5.86-3.8%$251.72 million$545.74 million-8.14
NuCana logo
NCNA
NuCana
1.5$4.76-6.3%$245.39 millionN/A-4.71Upcoming Earnings
Decrease in Short Interest
This page was last updated on 3/4/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.